Andere talen 89bio, Inc.

Aandelen

ETNB

US2825591033

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,08 ^USD	+2,25%		-7,54%	-18,71%

17/04	89bio, Inc. Benoemt Martin Babler tot lid van de Raad van Bestuur	CI
03/04	89bio Insider verkocht aandelen ter waarde van $575.153, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors	17/04
89bio, Inc. Appoints Martin Babler to Its Board of Directors	17/04
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	03/04
Sector Update: Health Care Stocks Gain Wednesday Afternoon	27/03
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	27/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	12/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)	11/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03
North American Morning Briefing : Stock Futures -2-	08/03
89bio to Participate in the Leerink Partners Global Biopharma Conference	05/03
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?	04/03
Top Premarket Gainers	04/03
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen 89bio, Inc.

Aandelen

ETNB

US2825591033

Andere talen

Filters